Company intelligence / Profile preview
Arkayli Biopharma
Madison, Wisconsin, United Statesarkayli.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Arkayli Biopharma is a private, clinical-entry biopharmaceutical company developing precision topical therapies for vascular anomalies, initially focused on infantile hemangioma. Its lead candidate, ARK001, is a proprietary pediatric topical esmolol gel designed to provide localized beta-blockade in infantile hemangioma while minimizing systemic drug exposure. In October 2026, the company reported that FDA had issued a Study May Proceed response to its IND and that it was preparing to initiate a Phase 1b study in infants with proliferating infantile hemangioma. (arkayli.com)
- Therapeutic areas
- Dermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Wisconsin
Beyond the preview
Go deeper on Arkayli Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arkayli Biopharma.